The invention provides a novel polyherbal composition useful for treating acute Hepatitis E virus infection including acute liver failure due to HEV infection, healthy Hepatitis B virus carriers who develop superadded hepatitis E virus infection, acute hepatitis B virus infection, and animal hepadna virus, therapeutic effects on hepatitis B virus infection and also used as a hepatoprotective agent, said composition comprising essentially extracts of plants Rheum emodi Wall., Phyllanthus amarus Linn., Eclipta alba Hassk., Andrographis paniculate Nees., and Picrorhiza kurroa Royle ex Benth., and optionally Fumaria officinalis, Tinospora cordifolia Miers., Terminalia chebula Retz., Cichorium intybus Linn., Tephrosea purpurea Linn. and Boerhaavia diffusa Linn.

Dabur Research Foundation

Hepatoprotective compositions and composition for treatment of conditions related to hepatitis B and E infection

The disclosure relates to a method of inhibiting synthesis of viral DNA in a mammal infected with a hepatitis B virus. This method includes administering at least one Phyllanthus component or substance to a mammal infected with the hepatitis B virus. It also includes inhibiting hepatitis B viral DNA synthesis in the mammal using the Phyllanthus component or substance. The disclosure also relates to a method of inhibiting viral gene expression in a mammal infected with a hepatitis B virus. This method includes administering at least one Phyllanthus component or substance to a mammal infected with the hepatitis B virus. It also includes inhibiting expression of at least one hepatitis B viral gene in the mammal using the Phyllanthus component or substance. These methods may form part of a method of preventing or treating hepatitis B infection.

Use of Phyllanthus constituents for treating or preventing infections caused by hepatitis B-viruses

An ayurvedic composition for prophylaxis and treatment of AIDS, flu, TB, and other immuno-deficiency conditions, and for liver diseases such as hepatitis and sclerosis, includes prescribed doses of extracts or isolates of two multi-component drugs in selected proportions. The first multi-component drug, LIVZON, consists of Phyllanthus niruri (292-310 mg.), Tinospora cordifolia (190-210 mg.), Phyllanthus emblica (90-110 mg.), Terminalia belerica (90-110 mg.), and Terminalia chebula (290-310 mg.); and the second multi-component drug, IMMINEX, consists of Holarrhena antidysenterica (40-60 mg.), Picrorhiza kurrooa (40-60 mg.), and Swertia chirata (15-35 mg.). The beneficial composition may be administered in the form of aqueous extracts, hard gelatin capsules, or mixed with syrup. The process of making the composition requires the basic ingredients to be cleaned, washed, dried and separated from all extraneous matter, after which they are powdered and extracts obtained therefrom with distilled water. The extracted material may be concentrated, granulated and dried at low temperature before the various ingredients are mixed in their selected proportions to form the necessary pharmaceutical dosage. Hard gelatin capsules or a syrup are other optional forms for dispensing the composition to patients.

Ayurvedic composition for the prophylaxis and treatment of AIDS, flu, TB and other immuno-deficiencies and the process for preparing the same

A pharmaceutical preparation comprising the methanol extractable components of Phyllanthus niruri L. is administered to patients suffering from hepatitis B virus infection in an amount effective for inhibiting the growth of said virus.

phyllanthus/hepatitis

Hepatoprotective compositions and composition for treatment of conditions related to hepatitis B and E infection

Use of Phyllanthus constituents for treating or preventing infections caused by hepatitis B-viruses

Ayurvedic composition for the prophylaxis and treatment of AIDS, flu, TB and other immuno-deficiencies and the process for preparing the same

Composition, pharmaceutical preparation and method for treating viral hepatitus

과학이 뒷받침하는 가장 완벽한 약초 데이터베이스